The global idiopathic inflammatory myopathy treatment market size is projected to reach USD 930.6 million by 2026, thereby exhibiting a CAGR of 4.6% during the forecast period. However, the market was worth USD 652.3 million in 2018. Fortune Business Insights™ published this information in an upcoming report, titled, “Idiopathic Inflammatory Myopathy Treatment Market Size, Share & Industry Analysis, By Disease Type (Dermatomyositis (DM), Polymyositis (PM), Inclusion Body Myositis (IBM), Necrotizing Autoimmune Myopathy (NAM), Others), By Treatment (Corticosteroids, Immunosuppressants, Intravenous Immunoglobulins, Others), By Route of Administration (Oral, Intravenous, Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019-2026.”
An Overview of the Impact of COVID-19 on this Market:

The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.

We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of corona virus outbreak across industries to help you prepare for the future.

Click here to get the short-term and long-term impact of COVID-19 on this [Market].
For More Information : https://www.fortunebusinessinsights.com/industry-reports/idiopathic-inflammatory-myopathy-treatment-market-100198

Urgent Need for Modern Therapeutics to Boost Growth
Nowadays, numerous new, modern therapies are emerging across the world. The demand for more effective therapeutics is also rising day by day. Earlier, the traditional treatment options had limitations for the doses of immunosuppressants and glucocorticoids. They could be used up to a certain extent. However, today’s innovative therapeutic options help in treating a wide range of myositis.
Moreover, as more and more difficult-to-treat cases of idiopathic inflammatory myopathy increased, mankind realized the dire need for state-of-the-art therapies. It further create da highunmet demand for treatment options. It is expected to be one of the most crucial idiopathic inflammatory myopathy treatment market growth drivers.

Polymyositis Segment to Lead: Rising Prevalence of this Myopathy
By disease type, the market is divided into necrotizing autoimmune myopathy (NAM), dermatomyositis (DM), inclusion body myositis (IBM),polymyositis (PM), and others. Out of these, the PM segment had acquired 44.4%idiopathic inflammatory myopathy treatment market share in 2018. It is expected to retain its leading position throughout the forecast period. It is likely to occur as PM is considered to be one of the highly occurring forms of myositis. It is also capable of causing disability in those people who do not seek medical treatment immediately. Besides, increasing prevalence of PM worldwide and its presence in numerous clinical pipeline by industry giants would propel the growth of this segment. The other segments have also contributed to the steady growth of the market.

More Trending Topics from Fortune Business Insights :
Medical Transcription Software Market , Share, Growth, Sales and Drivers Analysis Research Report 2026
Medical Transcription Software Market Exhibit a CAGR of 16.5% from 2019-2026; Advent of Cost-effective Cloud-integrated Software to Provide Impetus to Growth, says Fortune Business Insights